首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   18083篇
  免费   2992篇
  国内免费   407篇
耳鼻咽喉   261篇
儿科学   503篇
妇产科学   329篇
基础医学   1074篇
口腔科学   742篇
临床医学   906篇
内科学   2928篇
皮肤病学   184篇
神经病学   671篇
特种医学   363篇
外国民族医学   18篇
外科学   4185篇
综合类   1118篇
现状与发展   3篇
预防医学   1034篇
眼科学   120篇
药学   506篇
  3篇
中国医学   202篇
肿瘤学   6332篇
  2024年   50篇
  2023年   557篇
  2022年   840篇
  2021年   1205篇
  2020年   1151篇
  2019年   1134篇
  2018年   1075篇
  2017年   992篇
  2016年   917篇
  2015年   1066篇
  2014年   1421篇
  2013年   1376篇
  2012年   935篇
  2011年   921篇
  2010年   681篇
  2009年   744篇
  2008年   836篇
  2007年   710篇
  2006年   592篇
  2005年   546篇
  2004年   510篇
  2003年   447篇
  2002年   370篇
  2001年   288篇
  2000年   265篇
  1999年   229篇
  1998年   210篇
  1997年   195篇
  1996年   154篇
  1995年   111篇
  1994年   113篇
  1993年   87篇
  1992年   87篇
  1991年   82篇
  1990年   70篇
  1989年   55篇
  1988年   67篇
  1987年   51篇
  1986年   49篇
  1985年   49篇
  1984年   46篇
  1983年   34篇
  1982年   30篇
  1981年   28篇
  1980年   28篇
  1979年   23篇
  1978年   18篇
  1977年   12篇
  1976年   9篇
  1975年   7篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
51.
本文就加热及同时增加细胞内氧自由基水平对恶性胶质瘤细胞存活、增殖和细胞间隙连结通讯的影响做初步观察。用M.T.T法测定胶质瘤细胞存活率;用Ki-67抗增殖细胞核抗原单克隆抗体,通过免疫组织化学ABC染色分析胶质瘤细胞的增殖活性;用划痕染料示踪技术观察胶质瘤细胞的细胞间隙连结通讯。结果表明,H2O2和3AT能增强加热对胶质瘤细胞存活与增殖的抑制作用,促进胶质瘤细胞间隙连结通讯的改善,存在着明显的剂量和时间效应。实验结果提示,通过内外源性增加胶质瘤细胞内的氧自由基水平,将有助于强化加热治疗胶质瘤效果,并可以减少加热的剂且,降低副作用。  相似文献   
52.
Abstract: The results of an intensive treatment program for patients 16–60 yr of age with de novo acute myeloid leukemia are presented. The patients were given conventional induction treatment with daunorubicin and cytarabine. Patients not entering complete remission (CR) after 1 course of daunorubicin/cytarabine were given 1 course of amsacrine/etoposide/cytarabine. Those entering complete remission received 3 consolidation courses using mitoxantrone, etoposide, amsacrine and cytarabine. One hundred and eighteen patients were enrolled. Complete remission was attained after 1–2 courses in 90 patients (76%). Another 6 patients reached CR after 3–4 induction courses for a total CR rate of 81%. If feasible, patients were offered either allogeneic or unpurged autologous bone marrow transplantation. Twenty-four patients underwent allogeneic bone marrow transplantation; 15 in first remission, 8 in second remission, 1 in early relapse. Thirty patients below 56 yr of age underwent autologous bone marrow transplantation in first remission. The overall probability of survival at 4 yr was 34%, and for patients below 40 yr of age 50%. Leukemia-free survival was 35% for the whole cohort of patients; 52% for patients below 40 yr of age. Patients undergoing allogeneic or autologous bone marrow transplantation in first remission had an overall survival of 86% and 47%, respectively, while the probability of leukemia-free survival in these groups was 87% vs. 40% at 4 yr. The CR rate and long-term results of this intensive treatment program compare favorably with other recent studies using intensive consolidation with allogeneic or autologous bone marrow transplantation or high dose cytarabine.  相似文献   
53.
Therapeutic results are presented with follow-up examinations of at least 5 years (min. 5 years, max. 22 years) after 106Ru/106Rh plaque radiotherapy of posterior uveal melanomas. Out of 227 patients 146 (= 64.3%) could be treated successfully, 37 (= 16.3%) had to be enucleated and are alive, 44 (= 19.4%) died from metastases and 40 (17.6%) from other causes. 75.0% of all small melanomas (T1a) showed an excellent regression pattern to flat scars. Five years after treatment the survival rate was 83.7% (deaths from any causes) respectively 88.2% (deaths from metastases only) and 64.8% (deaths from any causes) respectively 79.7% (deaths from metastases only) ten years after irradiation. 106Ru/106Rh plaque radiotherapy can be recommended for small (Tla, b) and medium sized (T2) choroidal melanomas.  相似文献   
54.
Endocrine tumor of the pancreas is potentially malignant. A multicenter analysis of these tumors was conducted to clarity the present status of their surgical management and the subsequent long-term surgical results. The Japan pancreatoduodenectomy (JPD) study group carried out the study; 368 patients were enrolled and variables related to tumor characteristics, surgery, and survival were retrospectively analyzed. There were 222 patients with functioning tumor and 143 patients with nonfunctioning tumor. Malignant tumor was found in 140 of 368 (38%) of the patients, and 63/140 (45%) of these patients had metastatic lesion; the most common site of the metastasis was liver 34/136 (25%), followed by regional lymph nodes 26/136 (19%). Pancreatic resection was performed in 91% of patients with nonfunctional tumor and in 83% of those with malignant tumor, and 73% of the pancreatic resections were done with lymph node dissection. The overall 5-year actuarial survival rate was 76% in patients with malignant tumor. The actuarial 5-year survival rate was 93% in the patients without metastasis and 83% in patients who received curative resection. Multivariate analysis showed that the presence or absence of synchronous metastasis was the sole significant prognostic factor. The results suggest that: (i) malignant endocrine tumor of the pancreas is a curable malignancy when pancreatic resection with lymph node dissection is adopted and (ii) that synchronous metastasis is the dominant prognostic factor. This study was carried out as a group project. The authors' institutions are as follows  相似文献   
55.
In order to evaluate the effects of pentoxifylline on sperm motility and longevity, a controlled in-vitro study was conducted on normozoospermic donor semen samples using the Cellsoft automated system for sperm motility analysis. After incubation and selection, pentoxifylline was found to improve the recovery of spermatozoa and to increase their velocity. In the subgroup of progressively motile spermatozoa, curvilinear velocity was also enhanced. It is concluded that pentoxifylline has an effect on the vigour, but not on the pattern, of sperm motion. Pentoxifylline did not improve the motility characteristics of senescent spermatozoa in normozoospermic sperm samples. Sperm survival, as shown by supra-vital staining, and motility longevity both decreased with time after pentoxifylline treatment.  相似文献   
56.
57.
目的:评估全肠外营养(TPN)对老年晚期消化系统恶性肿瘤病人生存期的影响。方法:回顾性分析121例老年晚期消化系统恶性肿瘤病人TPN治疗后的生存期。结果:TPN治疗后,患者生存期不同程度延长,为9~126天,平均68.1天,多数在两月左右。结论:TPN可延长老年晚期消化系统恶性肿瘤病人的生存期。  相似文献   
58.
脑胶质瘤患者长期存活的临床因素分析   总被引:4,自引:0,他引:4  
目的 探讨胶质瘤患者长期生存相关的临床因素。方法 回顾性调查1980年5月-1995年5月间在本院手术治疗的胶质瘤患者,对收集的资料整理量化,建立Logistic回归模型(stepwise法)进行分析。结果 长期生存的胶质瘤患者102例,长期存活率占随访病例的43.9%(102/232)。病理级别、年龄、KPS、肿瘤部位、复发、复发后再手术、切除程度和手后放疗与胶质瘤患者的长期存活显著相关,其中复发后再手术、切除程度和手术后放疗是提高患者长期存活率的最重要因素。结论 应尽量在显微镜下行胶质瘤全切除,术后及时放疗和化疗;肿瘤复发时如KPS大于70,特别是第一次手术病理级别低者,应予再手术治疗。  相似文献   
59.
The survival of low birthweight infants £2000g born in the central Queensland area during the years 1979 to 1991 was examined. Five hundred and sixty such infants were either delivered at one of the two Rockhampton obstetric units (Rockhampton Base Hospital and the Mater Misericordiae Hospital) or retrieved from outlying central Queensland areas. Both hospitals had intensive care nurseries capable of ventilation and infants were transferred to tertiary centres only for cardiac or surgical treatment. The study involved all liveborn infants', including those with lethal malformations and all deaths up to the time of discharge. Survival rates were as follows: £500 g 0%, 501 £750 g 30%, 751 £1000 g 51%, 1001 ± 1500 g 79%, 1501 £2000g 93%. The survival of Aboriginal infants and outborn infants were found to be essentially the same as the overall group.  相似文献   
60.
麦胚提取物对辐射损伤修复的实验研究   总被引:2,自引:1,他引:1  
目的 研究麦胚提取物对小鼠辐射损伤修复的调节和保护作用。方法 采用辐射前或辐射同时饲喂一定量的麦胚提取物,观察小鼠经X射线一次性全身照射后的临床症状、30d存活率、骨髓微核率、外周血白细胞总数在不同时间的变化。结果 与对照组(单纯照射)比较,饲喂麦胚提取物可使小鼠的头面部皮肤、小肠黏膜、肾脏损伤症状得到明显改善;30d存活率为86.17%(P<0.01),提高存活率41.79%,保护系数为1.72;骨髓微核率4.62‰;比对照组(12.14‰)降低(P<0.01);外周血白细胞总数在7,13,20,30d均显回升(P<0.05,P<0.01,P<0.01,P<0.01)。结论 麦胚提取物对小鼠辐射损伤修复有一定程度的调节和保护作用,对于辅助肿瘤放射治疗具有重要意义。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号